Analysis Rohto Pharmaceutical Co., Ltd. (4527)
6/1/2024
Analysis of Rohto Pharmaceutical Co., Ltd. (4527)
Rohto Pharmaceutical Co., Ltd. is a Japanese company that specializes in the manufacturing and marketing of pharmaceuticals, cosmetics, and healthcare products. Looking at the recent financial data provided, we can see that the stock symbol 4527 has been experiencing some fluctuations in its stock price.- The RSI indicator, which measures the speed and change of price movements, has been hovering around the 30-40 range, indicating a neutral to slightly bearish sentiment in the market.
- The MACD indicator, which shows the relationship between two moving averages of the stock price, has been negative, suggesting a bearish trend in the stock.
- The Moving Average (MA) indicator, Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all showing a downward trend, indicating a decrease in the stock price over the given period.
Overall, based on the indicators and moving averages, it seems that Rohto Pharmaceutical Co., Ltd. may be facing some downward pressure in its stock price. Investors should closely monitor the stock and consider the overall market conditions before making any investment decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for the quarter ending on January 31, 2025, were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.43. The operating margin is 30.74% and the return on assets and equity are 22.07% and 147.25% respectively.
Moving on to stock statistics, the company has a short ratio of 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The average trading volumes for 10 and 90 days are 46.86 million and 57.50 million respectively. The stock outstanding shares are 15.33 billion, with 5.22% held by insiders and 57.59% by institutions.
Valuation metrics show a PEG ratio of 26.32, forward PE of 26.32, and trailing PE of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The enterprise to EBITDA and revenue ratios are 22.76 and 7.73 respectively, with a market capitalization of $2.92 trillion.
The stock price summary includes a beta of 1.26, 50-day moving average of $176.26, 200-day moving average of $181.04, and a 52-week low and high of $164.08 and $199.62 respectively, with a 52-week change of 6.85%.
Lastly, dividends and splits information shows a payout ratio of 14.93%, with a dividend date on May 16, 2024. The last split date was on August 31, 2020, with a 4-for-1 split factor. The forward annual dividend rate is $1, with a 5-year average dividend yield of 0.73% and a forward annual dividend yield of 0.53%. The trailing annual dividend rate is $0.97, with a trailing annual dividend yield of 0.51%.
Revenue estimate
The analysts' estimates for the future quarterly and annual sales of the company indicate a moderate growth trend.For the current quarter ending on June 30, 2024, the average estimate is $77,545,400,000, with a sales growth of 2% compared to the same period last year. The number of analysts providing estimates is 25.
Looking ahead to the next quarter ending on September 30, 2024, the average estimate increases to $85,501,800,000, with a sales growth of 3% compared to the previous year. Again, 25 analysts have contributed to these estimates.
For the current fiscal year ending on September 30, 2024, the average estimate for total revenue is $357,772,000,000, showing a 1% growth from the previous year. The number of analysts providing estimates for the annual sales is 38.
In the following fiscal year ending on September 30, 2025, the average estimate for total revenue is projected to be $380,772,000,000, indicating a more significant growth of 6% compared to the current fiscal year. The number of analysts remains at 38.
Overall, the estimates suggest a steady growth trajectory for the company's sales in both the short term and the long term, with the highest growth rate expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It is important to note that these are analyst estimates and actual performance may vary.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential challenge in maintaining profit margins.
3. The company's gross profit has fluctuated but generally increased over the years, reaching $169.1 billion in 2023.
4. Operating income has shown an upward trend, reaching $114.3 billion in 2023.
5. Net income has also been increasing, from $57.4 billion in 2020 to $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years.
7. The company has been able to manage its operating expenses to support the growth in revenue and income.
8. Overall, the financial performance of the company in terms of revenue and income has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2022 at $217,350,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase and issuance, as well as long-term debt issuance and payments.
6. Investing activities include significant amounts related to the sale and purchase of investments, with varying levels each year.
7. Overall, the company seems to be managing its cash flow effectively, with fluctuations in certain areas that may require further analysis and attention.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a range from $1.18 to $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is higher at $1.42, with a range from $1.33 to $1.51. This is also an increase from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS is projected to be $6.10, ranging from $5.95 to $6.41. This indicates growth from the EPS of $5.67 in the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a range from $5.92 to $7.31. This forecast suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
MACD of 4527
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
